IceCure Medical (ICCM) Q4 2025: U.S. Commercial Team to Triple as FDA Clearance Spurs Demand
IceCure Medical’s FDA clearance for ProSense in low-risk breast cancer is catalyzing a surge in U.S. adoption and global momentum. The company is leveraging new medical guidelines and reimbursement progress to drive installations across hospitals and clinics, while expanding its commercial organization to capture accelerating demand. Management’s focus on execution and regulatory expansion sets up a pivotal year as the pipeline converts to revenue and international opportunities advance.
Summary
- FDA Clearance Drives Adoption: Regulatory approval and new guidelines are unlocking U.S. market penetration for ProSense.
- Commercial Expansion Underway: IceCure is rapidly scaling its sales team and converting pipeline sites into installations.
- Global Regulatory Progress: Canada and Japan filings target broader international growth beyond the U.S. inflection.
Performance Analysis
IceCure Medical’s full-year revenue reached $3.4 million, with a record Q1 and accelerating momentum fueled by the October 2025 FDA clearance of ProSense for low-risk early-stage breast cancer. The company is now positioned as the only FDA-cleared provider in this segment, a status management expects will remain unchallenged for the foreseeable future due to the high bar for competing device approvals. Commercial traction is visible in both hospital and clinic installations, with notable wins at prestigious U.S. medical institutions and a growing pipeline of signed contracts.
Guideline recognition by the American Society of Breast Surgeons (ASBRS) and established reimbursement for ProSense are catalyzing physician and patient demand. Half of the company’s U.S. customer pipeline now stems from radiologists and surgeons, the core end-users for cryoablation procedures. Internationally, the FDA nod is serving as a credibility lever, with expanded usage and regulatory submissions in Canada and Japan. IceCure is executing on a dual commercial-clinical strategy, leveraging post-marketing studies and peer-reviewed data to further entrench ProSense in standard care pathways.
- U.S. Pipeline Conversion: Signed contracts and installations are ramping, including at top-tier hospitals and clinics.
- Reimbursement Tailwind: CPT-3 code established at $4,000 per procedure, with efforts underway to secure CPT-1 for broader and higher physician reimbursement.
- International Expansion: Regulatory submissions in Canada (targeting women 60+) and partnership with Terumo in Japan are advancing.
The business is now at an inflection point, with operational scale-up and regulatory momentum converging to support accelerating top-line growth.
Executive Commentary
"We are very pleased to see cryoablation receive deep recognition from a leading professional society, representing our targeted end-users, and believe it could represent a significant catalyst why it further validates the present role in modern breast cancer care as an option that prioritizes outcomes, cosmetic results, and patient choice."
Eyal Shamir, Chief Executive Officer
"By the end of the year, we intend to triple our commercial team in alignment with growing momentum and demand with the aim of getting broader penetration across the U.S."
Michael Polyview, Investor Relations (on behalf of CP Sales North America)
Strategic Positioning
1. FDA Clearance as Market Moat
ProSense is currently the only FDA-cleared cryoablation device for breast cancer, creating a significant first-mover advantage. Competing systems face high regulatory hurdles, as new entrants must submit full clinical follow-up data for 510K clearance. This regulatory moat allows IceCure to deepen relationships with hospitals and clinics without immediate competitive pressure.
2. Medical Society Endorsement and Reimbursement
The ASBRS guideline change recommending cryoablation for low-risk breast cancer is a critical validation, directly influencing physician behavior and payer policies. Coupled with established CPT-3 reimbursement and ongoing efforts to secure CPT-1, IceCure is reducing adoption friction and supporting broader access for both patients and providers.
3. Commercial Team Expansion and Pipeline Execution
Management is aggressively scaling the U.S. commercial organization, planning to triple the team by year-end to meet surging demand. The company’s pipeline includes both commercial and post-marketing study sites, with the latter required to perform reimbursable commercial procedures, accelerating revenue conversion and market penetration.
4. International Growth Levers
Regulatory filings in Canada and Japan extend the ProSense opportunity beyond the U.S., leveraging the credibility of FDA clearance to unlock new patient populations and drive adoption through local partnerships and clinical evidence generation.
5. Evidence Generation and Thought Leader Engagement
Ongoing independent studies and conference presentations are building a robust clinical dossier for ProSense, supporting physician education, patient awareness, and payer acceptance both in the U.S. and globally.
Key Considerations
This quarter marks a transition from regulatory validation to commercial execution for IceCure Medical, with strategic focus on pipeline conversion, reimbursement expansion, and international regulatory progress.
Key Considerations:
- Commercial Ramp Pace: The effectiveness of the expanded sales team in converting identified pipeline sites into installations will determine near-term revenue scaling.
- Reimbursement Progression: Transitioning from CPT-3 to CPT-1 codes could materially improve procedure economics for providers, influencing adoption rates.
- Regulatory Timelines Abroad: Approval outcomes in Canada and Japan will shape the company’s global revenue mix and long-term growth curve.
- Clinical Data Momentum: Independent studies and real-world evidence remain critical for sustaining guideline endorsements and payer support.
- Competitive Dynamics: The current regulatory moat must be monitored for any signals of new entrants or changes in FDA requirements.
Risks
Execution risk is elevated as IceCure scales its commercial team and ramps pipeline conversions, with the sales cycle ranging from a few to nine months. Reimbursement remains a gating factor, particularly the timing and scope of CPT-1 approval, which is not expected before early 2028. International regulatory decisions are subject to delays, and broader adoption depends on continued clinical evidence and physician advocacy. Any changes in guideline recommendations or emergence of new competitors could impact the company’s growth trajectory.
Forward Outlook
For Q1 and Q2 2026, IceCure expects:
- Increasing number of system sales and installations, particularly as the commercial team expands.
- Onboarding of up to 30 post-marketing study sites, each performing reimbursable commercial procedures.
For full-year 2026, management signaled:
- Continued revenue growth driven by U.S. adoption and international expansion.
Management highlighted several factors that will shape the coming quarters:
- Conversion of identified pipeline sites to commercial installations remains a top priority.
- Reimbursement improvements and regulatory decisions in Canada and Japan are key milestones.
Takeaways
IceCure Medical is at a commercial inflection, leveraging regulatory first-mover advantage and medical society endorsement to drive adoption of ProSense in the U.S. and abroad.
- Commercial Scale-Up: Tripling the U.S. sales team is a clear signal of confidence in pipeline conversion and market opportunity, but also raises execution risk as the company moves from pilot installs to broader penetration.
- Reimbursement and Evidence: Progress on CPT-1 and ongoing clinical data generation are critical for sustaining growth and supporting provider economics.
- Global Opportunity: Regulatory filings in Canada and Japan, if successful, could diversify revenue and establish IceCure as a global leader in minimally invasive breast cancer care.
Conclusion
IceCure Medical exits 2025 with regulatory validation and accelerating commercial momentum, positioning ProSense as a standard-of-care alternative for low-risk breast cancer. Execution on sales expansion, reimbursement, and international approvals will determine the pace and durability of its growth trajectory in 2026 and beyond.
Industry Read-Through
IceCure’s experience demonstrates the catalytic impact of regulatory clearance and guideline endorsement in medical device adoption, particularly for minimally invasive oncology solutions. The rapid scaling of sales infrastructure and focus on payer engagement highlight the importance of commercial readiness following regulatory milestones. Competitors in interventional oncology and device-based therapies should note the extended sales cycle and the need for robust clinical evidence to drive payer acceptance and physician adoption. Broader industry takeaway: regulatory and reimbursement alignment can unlock inflection points, but operational execution and continued clinical validation are essential for sustaining growth.